A lawyer, a film executive, a reality TV show winner and a stuffed raccoon named Parky. Last night’s opening ceremony of the 3rd World Parkinson Congress was not only varied, but it was also moving, inspiring and energizing.
That is when my husband John and I decided to attend the World Parkinson’s Congress 2013. Given the fact that it only happens once every three years, it’s the single largest worldwide gathering of all stakeholders in the Parkinson’s field, and we missed it the last go around — we weren’t going to let that happen again.
This week, members of the Parkinson’s community are gathering for the 3rd World Parkinson Congress in Montreal, Canada. Can’t make it to Montreal? PDF is bringing the WPC to you.
We’ll be reporting straight from Montreal, providing scientific updates, interviews with delegates, photos of the Parkinson’s Quilt display and more.
We’ll do our best to report back with help from our on-the-ground reporters, members of our People With Parkinson’s Advisory Council and more than 50 of our Research Advocates (check out their bios here).
I arrived early in Montreal for the 3rd World Parkinson Congress, which will officially start on Tuesday.
This Thursday will be a very special day for the Parkinson’s community: the debut of The Michael J. Fox show, a new TV comedy series starring the eponymous TV newscaster who lives with Parkinson’s disease. Michael has done so much to help this community — through the foundation he created, of course, but also by simply giving a “face” to Parkinson’s around the world. It is no exaggeration to say that he has transformed the way we look at PD and the people who live with it, and the level of urgency we all feel to bring resources to bear on ending it once and for all.
From James Beck, Ph.D., Vice President of Research Programs
Using old drugs as new cures seems like a surefire winner. It may be. However, after attending a recent meeting outside London hosted by the Cure Parkinson’s Trust, a small yet impactful British charity, it is clear that this path is neither clear nor easy. A committee of experts at the meeting evaluated and prioritized dozens of existing compounds – many are drugs used to treat other diseases – based upon their potential to stop Parkinson’s disease.